Lifeguard inhibition of Fas-mediated apoptosis: A possible mechanism for explaining the cisplatin resistance of triple-negative breast cancer cells

Biomed Pharmacother. 2016 Feb:77:161-6. doi: 10.1016/j.biopha.2015.12.022. Epub 2015 Dec 29.

Abstract

Triple-negative breast cancer does not express estrogen receptor-α, progesterone or the HER2 receptor making hormone or antibody therapy ineffective. Cisplatin may initiate p73-dependent apoptosis in p53 mutant cell lines through Fas trimerization and Caspase-8 activation and Bax up regulation and subsequent Caspase-9 activation. The triple-negative breast cancer, MDA-MB-231, overexpresses the protein Lifeguard, which inhibits Fas-mediated apoptosis by inhibiting Caspase-8 activation after Fas trimerization. The relationship between Fas, Lifeguard and cisplatin is investigated by down regulating Lifeguard via shRNA. Results demonstrate that cisplatin's efficacy increases when Lifeguard is down regulated. Lifeguard Knockdown MDA-MB-231 continue to decrease in cell viability from 24 to 48h after cisplatin treatment while no additional decrease in viability is observed in the Wild-Type MDA over the same period. Higher Caspase-8 activity in the Lifeguard knockdown MDA after cisplatin administration could explain the significant decrease in cell viability from 24 to 48h. This cell type is also more sensitive to Fas ligand-mediated reductions in cell viability, confirming Lifeguard's anti-apoptotic function through the Fas receptor. This research suggests that the efficacy of chemotherapy acting through the Fas pathway would increase if Lifeguard were not overexpressed to inhibit Fas-mediated apoptosis.

Keywords: Apoptosis; Caspase-8; Cisplatin; Fas; Lifeguard; Triple-negative breast cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / physiology
  • Apoptosis Regulatory Proteins / genetics*
  • Caspase 8 / biosynthesis
  • Caspase 9
  • Cell Line, Tumor
  • Cell Survival
  • Cisplatin / pharmacology*
  • Down-Regulation
  • Drug Resistance, Neoplasm / genetics*
  • Enzyme-Linked Immunosorbent Assay
  • Fas Ligand Protein / metabolism*
  • Female
  • Humans
  • Membrane Proteins / genetics*
  • Phosphatidylinositol 3-Kinases / metabolism
  • RNA, Small Interfering / genetics
  • Triple Negative Breast Neoplasms / genetics*
  • fas Receptor / metabolism

Substances

  • Apoptosis Regulatory Proteins
  • FAIM2 protein, human
  • Fas Ligand Protein
  • Membrane Proteins
  • RNA, Small Interfering
  • fas Receptor
  • Phosphatidylinositol 3-Kinases
  • Caspase 8
  • Caspase 9
  • Cisplatin